Cerebral Palsy ; physiopathology ; rehabilitation ; Child ; Disability Evaluation ; Humans ; Motor Skills ; Movement ; Muscle Spasticity ; physiopathology ; rehabilitation ; Neuropsychological Tests

Objective To investigate the effect of pidotimod combined with antiviral drugs on immunologic function and myocardial enzyme spectrum in children with infectious mononucleosis.Methods 94 cases of children with infectious mononucleosis selected in Wenzhou Children's hospital were randomly divided into control group and research group,47 cases in each group.The control group were given conventional antiviral treatment; On this basis,the research group were given pidotimod,2 weeks for one period of treatment.Before and after treatment,immune function,cell factors and myocardial enzyme spectrum were tested,the clinical symptoms,signs,the curative effect and complications were observed and compared.Results Compared with before treatment,after treatment,serum CD4+,CD4+/CD8+ IgA and IgG increased,CD8+ decreased,TNF alpha,IL-6,AST,LDH,CK,CK-MB decreased(P<0.05).Compared with the control group,in the research group,CD4+,CD4+/CD8+,IgA and IgG content is higher,CD8+ content is lower,the TNF alpha,IL-6,AST,LDH,CK,CK-MB content is lower(P<0.05).The time of antipyretic,angina fade,narrow lymph nodes,liver and spleen shrinks and length of hospital stay in the research group were shorter than that in the control group(P<0.05).The effective rate was 74.47％in the control group,lower than 91.49％of research group(P<0.05).Conclusion The curative is exact that pidotimod combined with antiviral drugs on the treatment of infectious mononucleosis.It could improve immune function,reduce myocardial enzyme spectrum and inflammation.

Stereotactic body radiotherapy (SBRT) is a treatment of high dose radiation in a single or small number fractions to the target areas.Compared with conventional radiotherapy,SBRT has the features of higher dose and better precision.The application in lung cancer can be summarized as the following three points:① SBRT has established the status of standard treatment for early (T1-2 N0 M0) nonsmall cell lung cancer (NSCLC) patients who unable or unwilling to undergo surgery.② The resuhs of preliminary application of SBRT in the operable NSCLC are not inferior to surgery.③ As for isolated metastases (1-3),the combination of systemic treatment and SBRT has been gradually accepted.This article makes a summary of this.

Hematopoietic stem cell transplantation (HSCT) has been widely performed for patients with various genetic and acquired malignant and non-malignant diseases.Central nervous system (CNS) complications are considered an important cause of morbidity and mortality after HSCT.This review discuss the main causes of CNS after HSCT such as infection,drug toxicity,graft-versus-host disease,metabolic encephalopathy,neurologic relapses etc,so as to benefit the early recognition of CNS complications and to improve the prognosis of patients after HSCT.

Homocysteine ( Hcy) is an independent risk factor for a variety of diseases and closely related to cardiac-cerebralvascu-lar diseases, neurological diseases, diabetes and diabetic com-plications. High homocysteine levels can significantly increase the recurrence risks of cardiac-cerebralvascular events and stroke in patients with stroke, leading to high all-cause mortality. The risk of Alzheimer’s disease is increased by 1. 8 fold when the concentration of Hcy is over 14 μmol·L-1 . For each 5 μmol· L-1 increase in plasma Hcy in diabetes patients, the mortality rate increases by 5 fold in the next five years. High Hcy triggers the pathogenesis of diseases via multiple mechanisms including oxidative stress, lesions of vascular endothelial cells, prolifera-tion of vascular smooth muscle cells, dysfunction of coagulation and lipid metabolism and genomic hypomethylation etc.

Objective To explore the clavicular hook plate in the treatment of distal clavicle fracture dislocation acromioclavicular joint clinical effects.Methods Twenty-three cases of Neer Ⅱ type distal clavicle fracture and 28 cases of Allman Ⅲ acromioclavicular joint dislocation line with open reduction and clavicular hook plate fixation.Results Fifty-one patients in this group have received 6-24 months of follow-up,an average of 18 months.2-3 weeks after the activities returned to normal off the shoulder,clavicle fractures were 3-12 months after bone healing and no-dislocation of acromioclavicular joint occur.According to Karlsson evaluation criteria:excellent in 40 cases,good in 9 cases and poor in 2 cases,excellent rate of 96.1％.Conclusion The clavicular hook plate fixation strength in the design and in line with the anatomical acromioclavicular joint physiological characteristics,surgical trauma,and has a fixed precise,allows early functional exercise.It is the ideal way to lock joint dislocation.

BACKGROUND: The improvement in production technology of new materials including artificial ligament reduces material rupture caused by fatigue and histocompatibility-related synovitis and other complications, leading to a wide application of artificial ligament. OBJECTIVE: To evaluate the histocompatibility and clinical curative effects of reconstruction of the anterior cruciate ligament (ACL) of the knee with ligament advanced reinforcement system (LARS) artificial ligament using arthroscopy. DESIGN: A completely randomized clinical design. SETTING: Department of Orthopedics, Second Affiliated Hospital of Soochow University. PARTICIPANTS: Thirty-two cases of ACL injury received LARS artificial ligament in the Department of Orthopedics, Second Affiliated Hospital of Soochow University From June 2005 to June 2006 and were recruited for this study. The 32 patients averaged 21 years old and were injured in sports. Prior to surgery, MRI showed injury to ACL and semilunar valve in all patients. Written informed consent for therapeutic contents was obtained from each patient. METHODS: Thirty-two patients with injury to ACL of the knee underwent arthroscopic ACL reconstruction. LARS was used to reconstruct the ACL. The LARS was produced by Laboratoire d'Application et de Recherche Scientifique, France (Certification No. CE0459, 1SO9002-EN46002). Artificial ligament was made of polyethylene terephthalate, which had the material type L021201 (left knee) and L021202 (right knee). Artificial ligament was designed to imitate the anatomic structure and biomechanical principle of artificial ligament with specification No. AC120 2BL(left knee) and No. AC120 2BR(right knee). The lot number for artificial ligament in China [import 03460468 (in 2004)]. All reconstructions were performed by a group of physicians who have worked for more than 10 years in the Department of Orthopedics, Second Affiliated Hospital of Soochow University and directed by a physician titled with doctor's tutor and chief physician. All included physicians were qualified to perform the surgery. The protocol of treatment was approved by the hospital's Ethics Committee. MAIN OUTCOME MEASURES: Biocompatibility of LARS artificial ligament was observed. Patients were followed up for 24 months on average to score knee function by Lysholm test and subjective satisfaction by Tegner test. RESULTS: All of 32 cases were followed up. The follow-up periods were 18 months (3 cases), 20 months (7 cases), 24 months (8 cases), 28 months (12 cases) and 30 months (2 cases). No complications, such as acute or chronic synovitis, LARS artificial ligament rupture, or limited range of motion were found. The knee joint function was ideal with the range of motion [0° to (128±11.56)°]. The postoperative scores with 85.6 ± 2.24 were significandy higher than the preoperative scores with 45.3±1.31 according to the Lysholm knee joint function evaluation system (P < 0.05). The instability of every knee disappeared with anterior drawer sign negative. Tegner's scores were also increased. CONCLUSION: The biocompatibility of LARS is optimal. LARS artificial ligament reconstruction showed excellent knee joint function and subjective satisfaction degree.

BACKGROUND: Of the many growth factors that can enhance bone formation, the bone morphogenic proteins (BMPs) are probably the most effective and most widely studied for applications requiring new bone growth. To analyze the effects, the gold standard is patient randomized control trials, however, only BMP-2 and BMP-7 have reached this level of investigation. OBJECTIVE: In this meta analysis the recent findings concerning the application of recombinant human bone morphogenic protein-2 (rhBMP-2) in tissue engineering and gene therapy, the options of its transfer means, as well as the ideal time of delivery is discussed. RETRIEVAL STRATEGY: The relevant articles published between January 1997 and December 2006 were searched for in Pubmed database by researcher of this article with the key words "recombinant human bone morphogenic proteins (rhBMPs), tissue engineering, gene therapy" in English. A total of 81 articles were selected and reviewed by the standards of: ① Having close relations with the application of rhBMP-2 in tissue engineering and gene therapy; ②The most recently published articles and articles in authority journals were chosen in the same field. Exclusion criteria: repetitive studies. LITERATURE EVALUATION: The main sources of literature are the application of rhBMP-2 in tissue engineering and gene therapy. Among the 52 selected articles, 12 are reviews or meeting reports, others are clinical or elementary experimental studies. DATA SYNTHESIS: BMPs are members of the TGF- β superfamily, which are released by osteoprogenitor cells and typically improve bone growth. The use of scaffolds, cells, and growth factors for bone regeneration is called bone tissue engineering. The application of rhBMP-2 in tissue engineering holds great promise for the augmentation and manipulation of bone and soft tissue repair. One potential alternative to direct rhBMP-2 delivery is to develop a biologic cellular delivery vehicle via gene therapy to enhance bone formation. The application of rhBMP-2 in gene therapy holds great promise for the augmentation and manipulation of bone and soft tissue repair. The research indicated that the dosing, time, and transfer mode of rhBMP-2 to the desired targets remain a facing challenge. Further studies should focus on the ideal dosing, time and method of delivery, which should be easily and reliably displayed, cost effective, and clearly controlled. CONCLUSION: The future of bone and soft tissue repair will likely be based on biologic augmentation of healing and tissue regeneration. The use of rhBMP-2 holds great promise for the augmentation and manipulation in tissue engineering and gene therapy.

Previous studies have proved that the effect of statins in both primary and secondary prevention of ischemic stroke, however, whether acute ischemic stroke needs to be treated with statins and the effect of statins pretreatment on acute ischemic stroke remain unclear. This article reviews the recent representative studies in this field, and analyzes the effects of the application of statins in the treatment of acute ischemic stroke on prognosis.